The "Biosimilar Compression": Is 2026 the Year of Affordable Immunotherapy?
A major shift in the 2026 global industry is the implementation of "Mass-Scale Biosimilar Integration." This year, to cater to the demand for sustainable healthcare, the Immunomodulators Market is navigating a wave of patent expirations for some of the world's top-selling biologics. This level of "Competitive Pricing" is the new gold standard, allowing middle-income nations to provide "Advanced...
0 Comments 0 Shares 33 Views 0 Reviews